- email:registrations@informa-ls.com
- phone:+44(0)20 7017 7481
24 days to go - register NOW!
Inhalation Drug Development: Emerging Trends and Markets
28 - 29 September 2010, Ambassadors Bloomsbury
Inhalation Drug Development: Emerging Trends and Markets
A breath of fresh air: New trends and solutions for your inhalation drug development programmes
Informa Life Sciences’ 2nd annual Inhalation Drug Development conference was developed in consultation with inhalation professionals, resulting in a programme targeting the needs of the industry. By attending the 2010 conference, delegates will gain:
- Extensive networking opportunities with inhalation experts, including representatives from Novartis, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva and Aeropharm
- Information on pertinent topics facing inhalation drug development, including improving bioequivalence and bioavailability, specific regulatory requirements for submissions in Europe and USA and optimising particle development, formulation and excipients to maximise aerosol performance and drug delivery
- A unique combination of presentations focussing on advances in inhalation development, including systemic delivery, inhaled vaccines, novel targets for COPD and trends in device development
2010 Conference Highlights
- The industry predicts that systemic inhaled drugs will account for approximately 9% of inhaled drugs in 2011 read more
- Injected vaccinations are known have problems due to fear of needles, and more common in developing countries, risk of infection and serious disease from unsterilised needles read more
- Of the estimated 500+ million sufferers of asthma and COPD worldwide, it is predicted that many of these are in developing countries read more
PLUS DON'T MISS...
MHRA PRESENTATION
Regulatory Perspective on Inhaled Product Development: Requirements and Common Pitfalls
Jospeh Lim, Senior Pharmaceutical Assessor, MHRA
Sanjeeva Dissanayake, Senior Medical Assessor, MHRA
..
Event Exhibitor
..
..
..
..
Promotional Participant
..
..
..
..
Media Partners
..
..
..
Speaker Panel
Speaker Panel
Robert Baughman
Vice President - Experimental Pharmacology
Mannkind Corporation
|
Birte Jensen
Principal Scientist - Respiratory Drug Delivery
Boehringer Ingelheim
|
Jussi Haikarainen
Devt Manager Inhalation Technology
Orion
|
Francesca Buttini
Post-doc Research Fellow, Dept of Pharmacy
University of Parma
|
Key Presentations and Speakers
- Systemic delivery of drugs by inhalation: Mannkind's experience with inhaled insulin
Robert Baughman, Vice President - Experimental Pharmacology, Mannkind Corporation, USA - New targets and treatments for COPD
Peter Barnes, Head of Respiratory Medicine, Imperial College London, UK - Bioavailability of inhaled drugs
John Patton, President and CEO, Dance Pharmaceuticals, USA
..
Join us on Linked In
..
..
..
Programme Updates
New Speaker Announcement
Oligonucleotides: a new treatment modality for respiratory disease
Mark Parry-Billings, ex-CEO, Topigen Pharmaceuticals Inc
Reviews
"Interesting, broad range of topics around the main topic, well organised"
"Good information and very good contacts made"
